Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp42576_8k.htm |
Exhibit 99.01
|
Press Release
|
 |
|
www.shire.com
|
Total Voting Rights
December 13, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with the Financial Conduct Authority's (the “FCA”) Disclosure and Transparency Rule 5.6.1A R, notifies the market of the following:
At close of business on December 12, 2013, the Company’s issued ordinary share capital comprised 586,061,385 ordinary shares of 5 pence each with voting rights and a further 9,823,536 ordinary shares held in treasury.
Therefore the total number of voting rights in the Company is 586,061,385. This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
|
Investor Relations
|
||
|
Eric Rojas
|
erojas@shire.com
|
+1 781 482 0999
|
|
Sarah Elton-Farr
|
seltonfarr@shire.com
|
+44 1256 894157
|
Notes to editors
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX